Clinical trials: Recurrent WHO Grade II Glioma
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00020150
- Testing
- O6-benzylguanine, temozolomide
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Seizure
Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors
RATIONALE: Levetiracetam and pregabalin are drugs that treat seizures. It is not yet known which drug is more effective in treating seizures caused by primary brain tumors.
- Trial name
- NCT00629889
- Testing
- levetiracetam, pregabalin
- Where
- 2 sites in Switzerland
- Volunteers
- 52 people
- Sponsor
- Dr Andrea Rossetti
Brain and Central Nervous System Tumors, Neuroblastoma
Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors
RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00503724
- Testing
- enzastaurin hydrochloride
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating young…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00030108
- Testing
- ixabepilone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma
Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
This pilot clinical trial compares gadobutrol with standard of care contrast agents, gadopentetate dimeglumine or gadobenate dimeglumine, before dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in diagnosing…
- Conditions
- Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma
- Trial name
- NCT02967380
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadobutrol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Southern California
Adult Brain Tumor, Adult Brain Stem Glioma
Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas
RATIONALE: Specialized radiation therapy, such as proton beam radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Conditions
- Adult Brain Tumor, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Ependymoma
- Trial name
- NCT01024907
- Testing
- proton beam radiation therapy, quality-of-life assessment, questionnaire administration
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
This phase II trial tests how well retifanlimab with bevacizumab and hypofractionated radiotherapy, compared to bevacizumab and hypofractionated radiotherapy alone, works in treating patients with glioblastoma that has come back…
- Trial name
- NCT06160206
- Testing
- Bevacizumab, Biospecimen Collection, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 134 people
- Sponsor
- Academic and Community Cancer Research United
Astrocytoma, Glioblastoma
CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
CC-90010-GBM-001 is a multi-center, open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD) and CNS penetration of CC-90010 following short-term interval therapy (4 daily doses ) prior to surgery, in subjects…
- Trial name
- NCT04047303
- Testing
- CC-90010
- Where
- 4 sites in United States, Spain
- Volunteers
- 20 people
- Sponsor
- Celgene
Brain and Central Nervous System Tumors, Metastatic Cancer
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more…
- Trial name
- NCT00784914
- Testing
- temsirolimus, pharmacological study, cytokine levels
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma
A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma
This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with…
- Conditions
- Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma, Refractory Low Grade Astrocytoma, Refractory Low Grade Glioma
- Trial name
- NCT04576117
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment
- Where
- 101 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma
- Trial name
- NCT00112619
- Testing
- topotecan hydrochloride
- Where
- 11 sites in United States
- Volunteers
- 19 people
- Sponsor
- Pediatric Brain Tumor Consortium
Glioblastoma
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
This study is being done to see if adding nivolumab to radiation therapy and bevacizumab can increase the effectiveness of the treatment for recurrent glioblastoma.
- Trial name
- NCT03743662
- Testing
- Re-irradiation (RT), Bevacizumab, Nivolumab
- Where
- 11 sites in United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the…
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma
- Trial name
- NCT04320888
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- 174 sites in United States, Australia and 1 more
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia.
- Conditions
- Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Chronic Myelogenous Leukemia
- Trial name
- NCT00053963
- Testing
- romidepsin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors
RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00098761
- Testing
- laromustine
- Where
- 10 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pediatric Brain Tumor Consortium
Recurrent Glioblastoma Multiforme, Malignant Glioma
Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
It has been shown that bevacizumab has significant anti-tumor activity in patients with recurrent glioblastoma multiforme. Vorinostat has modest anti-tumor activity against malignant glioma and can enhance the action of both…
- Conditions
- Recurrent Glioblastoma Multiforme, Malignant Glioma, Adult Brain Tumor
- Trial name
- NCT01738646
- Testing
- Vorinostat, Bevacizumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors, Lymphoma
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00544284
- Testing
- bortezomib, temozolomide, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
High Risk WHO Grade II Glioma, Recurrent/Post-Chemotherapy WHO Grade II Glioma
Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas
This is a pilot study of a vaccination regime that is designed to efficiently induce anti-tumor T-cell responses in patients with WHO grade II glioma.
- Trial name
- NCT01678352
- Testing
- Tumor Lysate Vaccine, Imiquimod
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Frank Lieberman
Brain and Central Nervous System Tumors
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of CNS tumors.
- Trial name
- NCT00025675
- Testing
- gefitinib
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Central Nervous System Tumors
Bevacizumab in Recurrent Grade II and III Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- TAVAREC (NCT01164189)
- Testing
- Bevacizumab, Temozolomide
- Where
- 39 sites in Austria, Belgium and 6 more
- Volunteers
- 155 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC